Compare JXN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JXN | RYTM |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | 3890 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | N/A | 2017 |
| Metric | JXN | RYTM |
|---|---|---|
| Price | $107.49 | $86.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $112.40 | ★ $131.14 |
| AVG Volume (30 Days) | 490.2K | ★ 921.3K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.36 | $54.90 |
| Revenue Next Year | $3.38 | $86.58 |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.84 | $55.31 |
| 52 Week High | $123.61 | $122.20 |
| Indicator | JXN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 49.53 |
| Support Level | $104.99 | $84.39 |
| Resistance Level | $109.34 | $93.51 |
| Average True Range (ATR) | 3.04 | 4.22 |
| MACD | 0.50 | 0.86 |
| Stochastic Oscillator | 76.21 | 78.67 |
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.